What this is
- How it works
- How it works isn't classified yet
- Tested for
- Schizophrenia, Cognitive Impairment
- Main trialPhase 2
- “This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.”In the company’s words, NCT06502964 on ClinicalTrials.gov
Other drugs for Schizophrenia
- CariprazineAbbVie · Phase 3
- EvenamideNewron Pharmaceuticals SPA · Phase 3
- LB-102LB Pharmaceuticals Inc. · Phase 3
- B2227Bostal Drug Delivery Co., Ltd · Phase 2/3
- Brexpiprazole for ER injectionBostal Drug Delivery Co., Ltd · Phase 2/3
- LYBALVIAlkermes, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2026 | Study of ALTO-101 in Patients With Schizophrenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026